🚀 VC round data is live in beta, check it out!
Prelude Therapeutics Valuation Multiples
Discover revenue and EBITDA valuation multiples for Prelude Therapeutics and similar public comparables like Antibiotice, Lavipharm, Heartseed, Alector and more.
Prelude Therapeutics Overview
About Prelude Therapeutics
Prelude Therapeutics Incorp is a clinical stage precision oncology company focused on discovering and developing small molecule therapies optimized to target the key driver mechanisms in cancers with high unmet needs. The company's pipeline includes four candidates currently in clinical development: PRT1419, a potent, selective inhibitor of MCL1; PRT2527, a potent and selective CDK9 inhibitor, PRT3645, a next-generation CDK4/6 inhibitor, and PRT3789 a first-in-class SMARCA2/BRM protein degrader.
Founded
2016
HQ
Employees
131
Website
Financials (LTM)
EV
$195M
Prelude Therapeutics Financials
Prelude Therapeutics reported last 12-month revenue of $23M.
In the same LTM period, Prelude Therapeutics generated had net loss of ($97M).
Revenue (LTM)
Prelude Therapeutics P&L
In the most recent fiscal year, Prelude Therapeutics reported revenue of $12M and EBITDA of ($103M).
Prelude Therapeutics expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $23M | XXX | $12M | XXX | XXX | XXX |
| EBITDA | — | XXX | ($103M) | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | (847%) | XXX | XXX | XXX |
| EBIT Margin | (431%) | XXX | (861%) | XXX | XXX | XXX |
| Net Profit | ($97M) | XXX | ($99M) | XXX | XXX | XXX |
| Net Margin | (416%) | XXX | (820%) | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Prelude Therapeutics Stock Performance
Prelude Therapeutics has current market cap of $280M, and enterprise value of $195M.
Market Cap Evolution
Prelude Therapeutics' stock price is $4.45.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $195M | $280M | 0.0% | XXX | XXX | XXX | $-1.58 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialPrelude Therapeutics Valuation Multiples
Prelude Therapeutics trades at 8.3x EV/Revenue multiple, and (1.9x) EV/EBITDA.
EV / Revenue (LTM)
Prelude Therapeutics Financial Valuation Multiples
As of April 20, 2026, Prelude Therapeutics has market cap of $280M and EV of $195M.
Equity research analysts estimate Prelude Therapeutics' 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Prelude Therapeutics has a P/E ratio of (2.9x).
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $280M | XXX | $280M | XXX | XXX | XXX |
| EV (current) | $195M | XXX | $195M | XXX | XXX | XXX |
| EV/Revenue | 8.3x | XXX | 16.0x | XXX | XXX | XXX |
| EV/EBITDA | — | XXX | (1.9x) | XXX | XXX | XXX |
| EV/EBIT | (1.9x) | XXX | (1.9x) | XXX | XXX | XXX |
| P/E | (2.9x) | XXX | (2.8x) | XXX | XXX | XXX |
| EV/FCF | 2.8x | XXX | 1.9x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Prelude Therapeutics Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Prelude Therapeutics Margins & Growth Rates
Prelude Therapeutics' revenue in the last 12 month grew by 177%.
Prelude Therapeutics' revenue per employee in the last FY averaged $0.1M, while opex per employee averaged $0.9M for the same period.
Prelude Therapeutics Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 177% | XXX | 312% | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | (847%) | XXX | XXX | XXX |
| EBITDA Growth | — | XXX | (25%) | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.1M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $0.9M | XXX | XXX | XXX |
| G&A Expenses to Revenue | 93% | XXX | 185% | XXX | XXX | XXX |
| R&D Expenses to Revenue | 375% | XXX | 777% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 961% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Prelude Therapeutics Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Prelude Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Antibiotice | XXX | XXX | XXX | XXX | XXX | XXX |
| Lavipharm | XXX | XXX | XXX | XXX | XXX | XXX |
| Heartseed | XXX | XXX | XXX | XXX | XXX | XXX |
| Alector | XXX | XXX | XXX | XXX | XXX | XXX |
| C4 Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Prelude Therapeutics M&A Activity
Prelude Therapeutics acquired XXX companies to date.
Last acquisition by Prelude Therapeutics was on XXXXXXXX, XXXXX. Prelude Therapeutics acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Prelude Therapeutics
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialPrelude Therapeutics Investment Activity
Prelude Therapeutics invested in XXX companies to date.
Prelude Therapeutics made its latest investment on XXXXXXXX, XXXXX. Prelude Therapeutics invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Prelude Therapeutics
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Prelude Therapeutics
| When was Prelude Therapeutics founded? | Prelude Therapeutics was founded in 2016. |
| Where is Prelude Therapeutics headquartered? | Prelude Therapeutics is headquartered in United States. |
| How many employees does Prelude Therapeutics have? | As of today, Prelude Therapeutics has over 131 employees. |
| Who is the CEO of Prelude Therapeutics? | Prelude Therapeutics' CEO is Krishna Vaddi. |
| Is Prelude Therapeutics publicly listed? | Yes, Prelude Therapeutics is a public company listed on Nasdaq. |
| What is the stock symbol of Prelude Therapeutics? | Prelude Therapeutics trades under PRLD ticker. |
| When did Prelude Therapeutics go public? | Prelude Therapeutics went public in 2020. |
| Who are competitors of Prelude Therapeutics? | Prelude Therapeutics main competitors are Antibiotice, Lavipharm, Heartseed, Alector. |
| What is the current market cap of Prelude Therapeutics? | Prelude Therapeutics' current market cap is $280M. |
| What is the current revenue of Prelude Therapeutics? | Prelude Therapeutics' last 12 months revenue is $23M. |
| What is the current revenue growth of Prelude Therapeutics? | Prelude Therapeutics revenue growth (NTM/LTM) is 177%. |
| What is the current EV/Revenue multiple of Prelude Therapeutics? | Current revenue multiple of Prelude Therapeutics is 8.3x. |
| Is Prelude Therapeutics profitable? | No, Prelude Therapeutics is not profitable. |
| What is the current net income of Prelude Therapeutics? | Prelude Therapeutics' last 12 months net income is ($97M). |
| What is the current FCF of Prelude Therapeutics? | Prelude Therapeutics' last 12 months FCF is $71M. |
| What is Prelude Therapeutics' FCF margin? | Prelude Therapeutics' last 12 months FCF margin is 302%. |
| What is the current EV/FCF multiple of Prelude Therapeutics? | Current FCF multiple of Prelude Therapeutics is 2.8x. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.